New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2013
10:17 EDTESRX, CTRXAnalyst says Express Scripts won't be hurt by private exchanges
Express Scripts (ESRX), which provides pharmacy benefit management services, is unlikely to be significantly hurt by private health insurance exchanges, research firm Jefferies believes. Investor worries about the impact of such exchanges on the company is overdone, the firm added. WHAT'S NEW: Following reports yesterday that several major companies are looking to place their retired workers into a private health insurance exchange, Jefferies analyst Brian Tanquilut wrote that such exchanges have been around for several years and have not significantly affected Express Scripts or its competitors. Moreover, many investors do not realize that Express Scripts' profit margins from the exchanges are not much lower than its margins from the large companies, Tanquilut contended. Finally, as a result of the shift of beneficiaries onto private exchanges, Express Scripts will have the opportunity to win new customers currently covered by its competitors, the analyst believes. He expects the stock to start advancing in the fourth quarter of this year and kept a Buy rating on the shares. WHAT'S NOTABLE: Express Scripts' stock fell slightly in an up market yesterday, as did shares of its competitor Catamaran (CTRX). TODAY'S PRICE ACTION: In early trading today, Express Scripts added 0.5% to $65 and Catamaran rose 0.45% to $45.60
News For ESRX;CTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
07:39 EDTCTRX, ESRXPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
October 9, 2014
09:12 EDTCTRXCatamaran acquisition in-line with expectations, says Leerink
Subscribe for More Information
07:37 EDTCTRXCatamaran acquisition likely to be well-received, says Oppenheimer
Subscribe for More Information
October 8, 2014
16:34 EDTCTRXCatamaran to acquire Salveo Specialty Pharmacy for $260M in cash
Catamaran announced that it has entered into a definitive agreement to acquire Salveo Specialty Pharmacy, an independent specialty pharmacy company headquartered in St. Petersburg, Florida with business operations in New York and California. Salveo manages approximately $400M in annual drug spend. The purchase price of $260M in cash represents a purchase price multiple of approximately 13x Salveo's trailing-twelve-month EBITDA and is expected to be funded through cash on the balance sheet. This acquisition is expected to be completed during Q4.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use